Global CD Antigen Cancer Therapy Market Size To Exceed USD 13.3 Billion By 2033 | CAGR of 11.95%
Category: HealthcareGlobal CD Antigen Cancer Therapy Market Size To Exceed USD 13.3 Billion by 2033
According to a research report published by Spherical Insights & Consulting, the Global CD Antigen Cancer Therapy Market Size Expected to Grow from USD 4.3 Billion in 2023 to USD 13.3 Billion by 2033, at a CAGR of 11.95% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 234 pages with 110 Market data tables and figures & charts from the report on the "Global CD Antigen Cancer Therapy Market Size, Share, and COVID-19 Impact Analysis, By Therapy Type (Monoclonal Antibodies, (CAR) T-cell Therapy, Bispecific Antibodies), By Antigen Type (CD19, CD20, CD22, CD30), By Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, Solid Tumors), By End-User (Diagnostic Testing, Therapeutic Treatment, Research and Development), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.'" Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/cd-antigen-cancer-therapy-market
CD antigen cancer therapy involves targeting specific CD markers on cancer cells, which allows for more precise treatment. CAR T-cells and monoclonal antibodies, for instance, target cancers specifically by detecting cell membrane proteins, increasing therapy efficacy while minimizing injury to healthy cells. This strategy enhances the accuracy and efficacy of targeted cancer therapy. Furthermore, the CD antigen cancer therapy market is growing rapidly, resulting in increased global cancer incidence and the need for targeted therapies. Furthermore, government programs and agreements between pharmaceutical businesses and research institutes promote innovation and accelerate clinical trials, creating enormous prospects for industry players. However, accurate regulatory requirements for CD antigen cancer therapy hamper market expansion, and developing therapy, research, and strategies to target CD antigen cancer therapy costs time and money.
The (CAR) T-cell therapy segment is expected to hold the largest share of the global CD antigen cancer therapy market during the anticipation timeframe.
Based on therapy type, the global CD antigen cancer therapy market is categorized as monoclonal antibodies, (CAR) T-cell therapy, and bispecific antibodies. Among these, the (CAR) T-cell therapy segment is expected to hold the largest share of the global CD antigen cancer therapy market during the anticipation timeframe. CAR T-cell therapy is extremely effective at targeting specific cancer cells, resulting in long-term responses in patients with certain types of blood cancers, such as leukaemia and lymphomas. Furthermore, ongoing developments in CAR T-cell therapy, such as enhanced cell engineering techniques and the creation of new generations of CAR T-cells, are improving treatment outcomes and broadening applications.
The CD19 segment is expected to grow at the fastest CAGR during the anticipation timeframe.
Based on the antigen type, the global CD antigen cancer therapy market is categorized as CD19, CD20, CD22, and CD30. Among these, the CD19 segment is expected to grow at the fastest CAGR during the anticipation timeframe. CD19 treatments, such as Kymriah and Yescarta, are driving market growth due to their high success rate in treating B-cell malignancies like leukaemia. Furthermore, recent approvals and extended indications, as well as continuing trials for innovative medications, have boosted their popularity and accelerated segment growth.
The leukaemia segment is expected to hold the largest share of the global CD antigen cancer therapy market during the anticipation timeframe.
Based on cancer type, the global CD antigen cancer therapy market is categorized as leukaemia, lymphoma, multiple myeloma, and solid tumours. Among these, the leukaemia segment is expected to hold the largest share of the global CD antigen cancer therapy market during the anticipation timeframe. Leukaemia, particularly B-cell malignancies like acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL), is responsible for an important number of cancer cases globally. The increasing incidence of malignant malignancies raises a requirement for appropriate treatments.
The therapeutic treatment segment is expected to grow at the fastest CAGR during the anticipation timeframe.
Based on the end-user, the global CD antigen cancer therapy market is categorized as diagnostic testing, therapeutic treatment, research and development. Among these, the therapeutic treatment segment is expected to grow at the fastest CAGR during the anticipation timeframe. The development of CD antigen-targeted drugs, such as CAR T-cell treatments, has culminated in improved treatment efficacy and patient survival rates, generating new interest and financing for therapeutic approaches. Furthermore, continued R&D operations aimed at refining existing pharmaceuticals and developing new therapies encourage innovation and increase the therapeutic options available to patients, hence driving market growth.
North America is projected to hold the largest share of the global CD antigen cancer therapy market over the anticipation timeframe.
Get more details on this report -
North America is projected to hold the largest share of the global CD antigen cancer therapy market over the anticipation timeframe. In North America, the CD antigen cancer therapy industry is shifting towards precision medicine and personalized oncology, with major expenditures in genetic profiling and targeted therapy development. In addition, there is an emphasis on collaborative research activities between academia, industry, and government institutions to foster innovation and accelerate pharmaceutical discovery and development.
Europe is expected to grow at the fastest CAGR growth of the global CD antigen cancer therapy market during the anticipation timeframe. In Europe, developments in the CD antigen cancer therapy market centre on regulatory harmonization and quicker approval processes to enable for faster access to innovative therapies. There is also a greater emphasis on cost-effectiveness and value-based healthcare models, which promote the adoption of CD antigen therapies that provide superior clinical outcomes and cost savings over traditional treatments.
Major vendors in the global CD antigen cancer therapy market are Altor BioScience, Regeneron Pharmaceuticals, Moderna, Inc., Kite Pharma, Roche, Adaptive Biotechnologies, Cartesian Therapeutics, Immatics, Pfizer, Magenta Therapeutics, ADCT Therapeutics, Cellectis, Cytokinetics, Gilead Sciences, Inc., and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Developments
- In April 2023, Omisirge (omidubicel-onlv), an allogeneic cell treatment developed by Gamida Cell Ltd, was approved by the US FDA for the treatment of hematologic malignancies in adults and children aged 12 and older.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global CD antigen cancer therapy market based on the below-mentioned segments:
Global CD Antigen Cancer Therapy Market, By Therapy Type
- Monoclonal Antibodies
- (CAR) T-cell Therapy
- Bispecific Antibodies
Global CD Antigen Cancer Therapy Market, By Antigen Type
- CD19
- CD20
- CD22
- CD30
Global CD Antigen Cancer Therapy Market, By Cancer Type
- Leukaemia
- Lymphoma
- Multiple Myeloma
- Solid Tumors
Global CD Antigen Cancer Therapy Market, By End-User
- Diagnostic Testing
- Therapeutic Treatment
- Research and Development
Global CD Antigen Cancer Therapy Market, By Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?